Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)
Visit JP Morgan's Website
Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin
STAY IN TOUCH WITH OUR LATEST NEWS
Subcribe to our newsletter
By continuing to browse this website, you agree to the use of such cookies.